ReviewHeliyon2025
Targeted-release budesonide: A comprehensive review on its potential in IgA nephropathy.
Review in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation.Kidney international reports · 2026Review
- Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is characterized by the presence of IgA deposits in the glomerular mesangium, representing a prevalent form of primary glomerulonephritis worldwide. This condition is associated with a significant risk of progression to end-stage renal disease (ESRD). Hypertension, proteinuria, and reduced glomerular filtration rate (GFR) are established risk factors. Although angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are currently the first-line treatments, they do not adequately mitigate the risk of disease progression. Budesonide is a potent corticosteroid that has been utilized for many years in the treatment of inflammatory diseases. Recently, a novel formulation, targeted-release budesonide (TRF-budesonide), was developed to facilitate drug release specifically in the distal ileum to treat IgAN. This review synthesizes the existing evidence on the impact of TRF-budesonide in IgAN, covering its pathogenesis, efficacy, and safety. It also explores comparisons between TRF-budesonide and other therapeutic options, highlighting the advantages of TRF-budesonide in reducing proteinuria and preserving renal function. While TRF-budesonide has demonstrated promising efficacy and safety in short- and medium-term studies, showcasing its potential as a valuable treatment option for IgAN, further high-quality randomized controlled trials are needed to comprehensively evaluate its long-term efficacy and safety. Such research will pave the way for more personalized and precise treatment options for patients with IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.